Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02412982 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients
A Phase 4 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 103
- Enrollment target
NCT02412982: Completed Phase 4 study, sponsored by University of Cincinnati.
NCT02412982 is a Phase 4 study that has completed, run by University of Cincinnati. The registered enrollment target is 103 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02412982, a Phase 4 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 103 participants
- Enrollment target
Study Summary
This is a pilot study to determine if anti-thrombin III (AT-III) serum concentrations differ between patients with normal versus subtherapeutic anti-Xa trough concentrations when placed on enoxaparin 30 mg twice daily for VTE prophylaxis. Secondarily, this study will compare two enoxaparin dosing strategies.
Primary Outcome
Serum AT-III (% activity) will be compared between the control group and the intervention group patients (combined) after the third dose of enoxaparin 30 mg every 12 hours once initiated at the discretion of the trauma service per current VTE prophylaxis protocol
Interventions
- DRUG Enoxaparin 40 mg q12h
- DRUG Enoxaparin 30 mg q8h
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2016-03 |
| Est. Completion | 2019-01 |
| Phase | Phase 4 |
What the finished NCT02412982 record still lists
NCT02412982 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Enoxaparin 40 mg q12h is the first listed.
NCT02412982 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02412982 about?
NCT02412982 is a clinical study titled "Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients". This is a pilot study to determine if anti-thrombin III (AT-III) serum concentrations differ between patients with normal versus subtherapeutic anti-Xa trough concentrations when placed on enoxaparin 30 mg twice daily for VTE prophylaxis. Secondarily, this study will compare two enoxaparin dosing st...
What is the current status of trial NCT02412982?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 103 participants. The study started on 2016-03. Estimated completion is 2019-01.
What interventions are being tested in trial NCT02412982?
The interventions under investigation include: Enoxaparin 40 mg q12h (DRUG), Enoxaparin 30 mg q8h (DRUG).
Who is sponsoring clinical trial NCT02412982?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02412982's enrollment target sits among peer trials
103 760th of 2000 higher than 1,237 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia